Platinum Doublet

Phase 2Small molecule

Platinum Doublet is one of 60 small molecule programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CarcinomaActive, not recruiting

Resectable NSCLCActive, not recruiting

ImmunochemotherapyRecruiting

Non-Small Cell Lung CarcinomaPhase 2

Active, not recruiting

Resectable NSCLCPhase 2

Active, not recruiting

ImmunochemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

51 competitors in Non-Small Cell Lung Carcinoma

#DrugCompanyPhaseTrials

Tabrecta

Retevmo

Rozlytrek

Lumakras

Taxol

4 6

Keytruda

Merck & Co.

Phase 3

4 7

Tepmetko

EMD Serono

Approved

—8

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Abraxane

2 10

Imjudo

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Autoimmune

NCT03816345

Q2 2030

Phase 2Active, not recruiting

Non-Small Cell Lung Carcinoma

NCT05500092

Phase 2Recruiting

Immunochemotherapy

NCT06977074

Phase 2Active, not recruiting

Resectable NSCLC

NCT03916627

Clinical

Trials by Indication[1]

Resectable NSCLC1 trial

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT03916627·65 enrolled

Immunochemotherapy1 trial

PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

Recruiting·SSun Yat-sen University·Phase 2·NCT06977074·83 enrolled

Autoimmune1 trial

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816345·300 enrolled

Non-Small Cell Lung Carcinoma1 trial

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Active, not recruiting·MMontefiore Medical Center·Phase 2·NCT05500092·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Platinum Doublet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platinum Doublet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platinum Doublet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

Platinum Doublet

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2030

Trials by Indication[1]

Resectable NSCLC1 trial

Immunochemotherapy1 trial

Autoimmune1 trial

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News